Walleye Capital’s VistaGen Therapeutics VTGN Stock Holding History

Walleye Capital’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-67,770	Closed	-$241K	–	5187
2025 Q3	$241K	Buy	+67,770	New	+$202K	﹤0.01%	3190

Other funds holding VTGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Walleye Capital's VTGN Position: Q4 2025 in Review

Walleye Capital sold out of VistaGen Therapeutics (VTGN) in Q4 2025, closing a stake of 67,770 shares — an estimated $241K sold.

Walleye Capital first reported a position in VTGN in Q3 2025 and held it in 1 quarter. The position peaked at $241K in Q3 2025. 55 funds tracked by Wall St. Rank hold VTGN as of Q4 2025.

Walleye Capital reported no remaining VistaGen Therapeutics position as of Q4 2025 after selling out during the quarter.
Walleye Capital sold 67,770 VistaGen Therapeutics shares in Q4 2025, an estimated $241K.
Walleye Capital first reported a position in VistaGen Therapeutics in Q3 2025 and held it in 1 quarter.
Walleye Capital's VistaGen Therapeutics position peaked at $241K in Q3 2025.
55 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.